MEET THE NORTHSKY TEAM

Rob Harris, past founder and President and CEO of Tribute Pharmaceuticals, has over 35 years of pharmaceutical industry experience in both Canada and the United States in sales, marketing, business development and general management.  

Rob most recently served as Executive Chair of Nuvo Pharmaceuticals Inc.  Rob also has previous experience at Biovail Corporation as VP of Business Development where he was involved, led and successfully concluded numerous business development transactions, including the licensing of new chemical entities, the acquisition of mature products, the completion of co-promotion deals, distribution agreements, product development and reformulation transactions. Rob joined Biovail in 1997 as the General Manager of Biovail Pharmaceuticals Canada at a time when the company experienced rapid growth in the Canadian division. Before Biovail, Rob worked in various senior commercial management positions during his twenty-year tenure at Wyeth-Ayerst (now Pfizer Inc.), including its animal health group and has been involved in numerous product launches during his career.  

Rob also serves as a member of the Board of Directors of Trudell Medical Group and Grey Wolf Animal Health. Previous board experience includes Nuvo Pharmaceuticals Inc., Origin House, Tribute Pharmaceuticals, Aralez Pharmaceuticals Inc. and  Stellar Pharmaceuticals Inc. 

Ms. Demerino is a seasoned pharmaceutical industry executive with over 20 years of experience in diverse industries, including healthcare, clean energy, manufacturing, and financial institutions.  

Kelly has held numerous senior leadership roles, ranging from CFO at Cyclone Manufacturing Inc, an aerospace manufacturer; Interim CFO for Nuvo Pharmaceuticals Inc. and VP Finance for Miravo Healthcare. Her diverse experience includes raising capital via public offerings and private placements, M&A integrations, product launches, and the execution of in-licensing and out-licensing deals.

Kelly is a Chartered Professional Accountant (CPA), a Chartered Accountant (CA), and a Certified Internal Auditor (CIA), and holds a Bachelor of Commerce degree from Mount Allison University.

Dr. Chiasson has approximately 30 years’ experience in research and development and executive management roles in pharmaceuticals and biotechnology. 

In his most recent role as VP Operations and Chief Scientific Officer at Nuvo Pharmaceuticals Inc., he was responsible for oversight of regulatory, safety, medical/clinical and quality. As part of his operational duties, Bernard also oversaw supply chain and in-house and outsourced manufacturing and was a member of the Board of Directors at Nuvo Pharmaceuticals DAC in Ireland. Bernard is currently President of BJC Integrated Scientific Management Inc., a boutique consulting firm that provides management consulting in various scientific areas. 

He has worked on small molecules, biologics and medical devices at various stages of product development including the final registration phase with Health Canada and the US FDA. He is experienced in a variety of therapeutic areas and has developed strategies and franchise management approaches for pre-market and marketed products in various categories. 

Bernard obtained his industry training with Novartis, Draxis Health, Bayer Biologics, Amgen, Tribute Pharmaceuticals, Nuvo Pharmaceuticals and held the position of Vice President of Strategic Regulatory Affairs and Medical Services at Optum. 

Dr. Chiasson is a trained neuroscientist and pharmacologist and received his training at Dalhousie University and the University of Toronto.